PDI signs four-year deal with Novartis

Share this article:
Contract sales firm PDI signed a four-year agreement with Novartis to deploy a field force promoting Elidel, a second-line eczema treatment for patients older than 2 years, according to Kim Golodetz, a spokesperson for PDI. 

The deal calls for deployment of “approximately 100 full-time equivalent sales representatives who will call upon physicians nationwide,” a PDI statement said. 

After losing contracts with GlaxoSmithKline and Sanofi-Aventis in 2006, PDI rebounded with a “top-five pharmaceutical company” contract in 2007.  

In February, the company named Peter Tilles president of its TVG marketing research and consulting unit.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.